Optimal combination of plasma filters in therapeutic double filtration plasmapheresis fo in kidney transplant recipients with higher immunological barrier

Optimal combination of plasma filters in therapeutic double filtration plasmapheresis fo in kidney transplant recipients with higher immunological barrier - Optimal combination of plasma filters in therapeutic double filtration plasmapheresis fo in kidney transplant recipients with higher immunological barrier

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017605

Enrollment

Registered

2015-05-18

Start date

2015-06-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplantation with higher immunological barrier

Interventions

Different type of plasmafilter (EC-50W, Asahi-Kasei Medical) which has smaller pore size than conventional type (OP-08W, Asahi-Kasei Medical) is used as primary filter to preserve serum fibrinogen in

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. kidney transplant recipients 15 y.o. or higher. 2. Immunological high risk recipients such as ABO-blood type incompatible or anti-donor-HLA antibody positive those who require pre-transplant antibody removal. 3. recipients who have sufficient informed consents.

Exclusion criteria

Exclusion criteria: 1. kidney transplant candidates who experienced any unpredictable adverse events. 2. those recipients who don't have informed consents. 3. Those recipients whom the principal investigator judged as inappropriate candidates for the study.

Design outcomes

Primary

Measure	Time frame
To assess and compare with conventional plasmapheresis in terms of the efficacy and selectivity in antibody removal.	—

Countries

Japan

Contacts

Public ContactDaiki Iwami

Hokkaido University Graduate School of Medicine Department of Renal and Genitourinary surgery

iwamidaiki@ybb.ne.jp011-706-5966

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026